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TO THE EDITOR
MicroRNA (miR) is a class of non-
coding RNA, modulating gene expres-
sion through negative regulation of
target gene expression. Currently, 41,000
human miRs have been identified
which can have crucial roles during
(tuning of) T-cell activation and dif-
ferentiation (Lindsay, 2008; Lodish
et al., 2008), and there is increasing
evidence for a role of miRs in the
pathogenesis of lymphoma and leuke-
mia (Croce, 2009).
Recent miR array studies indicate
that a considerable amount of miRs
show aberrant expression in cutaneous
T-cell lymphoma (CTCL), including
Se´zary (Sz) syndrome (Ballabio et al.,
2010; Narducci et al., 2011; Ralfkiaer
et al., 2011; van Kester et al., 2011).
However, findings from these array-
based analyses are not fully consistent,
perhaps as a result from variant techno-
logical approaches and disadvantages
such as background noise and cross-
hybridization problems. These drawbacks
can be overcome by next generation
(deep) sequencing, which offers increased
sensitivity and specificity, and has an
unlimited detecting range.
Maybe even more importantly, deep
sequencing also reveals the proportion
of individual miRs in relation to the
complete miRNome, which provides
insights into complexity of miRNomes,
as well as permits the discovery of
previously unreported miRs (Creighton
et al., 2009) information that cannot
be collected using miR array-based
platforms.
Using deep-sequencing technology
(Supplementary Information online), we
quantitatively and qualitatively ana-
lyzed the miRNomes of CD4þ T cells
isolated from the peripheral blood of
Sz patients (diagnosed according to
criteria described in Willemze et al.
(2005)). For comparison, we not only
determined the miRNomes of CD4þ
T cells from healthy controls, but
also from erythroderma secondary to
atopic dermatitis (EAD) patients, as a
clinically relevant benign counterpart
of Sz. Using the miRBase annotation,
612 known miR sequences were iden-
tified in all 20 sequenced samples.
Quantitative analysis revealed that
the genome-wide miR expression in
T cells of Sz patients, EAD patients,
and healthy donors was rather similar.
We found that a small amount of
abundantly expressed miRs contributed
to the major part of the each miRNome,
e.g., the 20 most abundant miRs con-
tributed to 490% of each miRNome
(Figure 1a).
When compared with EAD patients,
11 miRs were found to be statistically
significantly differentially expressed
(Figure 1b), including upregulation of
miR-214/214* and miR-199a/199a* in
Sz as the most profound difference.
In comparison with healthy donors
(used as an additional control), 17 miRs
were identified to be significantly
differentially expressed in Sz patients
(Figure 1c); again, upregulation of
miR-214/214* and miR-199a/199a*
was the most prominent distinction.
For the upregulated miRs, in compar-
ison to healthy controls, our deep-
sequence data are well in agreement
with previously published results: four
out of six miRs identified via deep
sequencing as being upregulated in Sz
versus controls were also identified
in array studies (miR-214, miR-199a,
miR-199a*, and miR-486).
Seven out of the 13 miRs identified
via deep sequencing as being down-
regulated in Sz as compared with
healthy controls have also been reported
to be lower expressed using array-based
analysis (miR-19a, miR-192, miR-140,
miR-146b, miR-30e, miR-142, and miR-
31). As these miRs are also low abun-
dantly expressed in EAD, an association
with the malignant character of Sz is not
expected. In comparison with EAD, we
identified seven miRs that were signi-
ficantly lower expressed and also down-
regulated in many other tumors (Calin
and Croce, 2006), thus probably reflect-
ing a general cancer miR signature.
Previous array-based studies showed
that the major change in the Sz miRNome
in comparison with healthy cells was
downregulation of many more miRs,
e.g., an additional 25 (Narducci et al.,
2011) or 104 miRs (Ballabio et al.,
2010). This discrepancy with the cur-
rent deep-sequencing data may result
not only from the different technologies
used (including statistical analysis) but
also from the selection of reference
material. For instance, in our compar-
ison we used CD4þ T cells isolated by
negative selection (‘‘untouched’’),
whereas positively selected CD3þ
and CD4þ T cells were used in the
studies of Ballabio et al. (2010) and
Narducci et al. (2011).
To discover hitherto previously
unreported miRs, we used the miR-
Deep2.0 pipeline to map and analyze
all the reads to the human genome
for the three different groups: Sz
(n¼12), EAD (n¼ 4), and healthy con-
trols (n¼ 4). A list with all miRDeep
scores of 41.0 and additional infor-
mation are available as Supplementary
Information online (Supplementary
Table S3 online). Although this analysis
revealed many previously unreported
miRs, most of them were expressed
Abbreviations: CTCL, cutaneous T-cell lymphoma; DNM3os, dynamin 3 opposite strand;
EAD, erythroderma secondary to atopic dermatitis; miR, microRNA; Sz, Se´zary
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at very low levels (o100 copies per
million read counts). The most abundant
miR is found to be located on the positive
strand in chr12:130494576–130494683.
However, this miR is also expressed
in benign controls (EAD and healthy
donors) at comparable levels.
In the course of analyses, we
observed many sequence variations in
comparison with sequences deposited
in miRBase. These deviancies consisted
of single-nucleotide substitutions, 30
and/or 50 deletions and extensions, as
well as non-template additions (tailing).
This is in particular noteworthy for
miR-21, which is proposed and dis-
puted as diagnostic marker for CTCL
(Narducci et al., 2011; Ralfkiaer et al.,
2011). Deep sequencing shows that
the major form of this miR consists of
23 nucleotides (50-UAGCUUAUCAGA
CUGAUGUUGAC-30) in all samples,
whereas arrays and commercially avail-
able PCR assays are designed for the
detection of a 22-nucleotide-long, less
prevalent, and variant miR.
As mature miR-199a and 199a* can
arise from different precursors, we
measured precursor expression of pre-
miR-199a1, pre-miR-199a2, and pre-
miR-199b, and compared these data with
pre-miR-214 expression. Quantitative
PCR analysis demonstrated upregula-
tion and high expression of pre-miR-
199a2 and pre-miR-214 in Sz, while
expression levels of pre-miR-199a1 and
pre-miR-199b did not differ signifi-
cantly between Sz, EAD, and healthy
donors (Figure 2). Pre-miR-199a2 and
pre-miR-214 are located as a tandem in
a single transcript, so-called dynamin 3
opposite strand (DNM3os), which is
thought to be transcriptionally activated
by TWIST1 (Lee et al., 2009), a transcrip-
tion factor which is known to be over-
expressed in Sz (van Doorn et al., 2004).
In sum, our deep-sequence analysis
shows that the major changes in the
miR repertoire of Sz cells converge to
a single determinant, i.e., expression
of DNM3os. This transcript harbors four
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Figure 1. Deep-sequence analysis of expressed microRNAs (miRs) in Se´zary (Sz) syndrome, erythroderma secondary to atopic dermatitis (EAD), and
healthy controls. The expression of each miR was normalized within samples, and miRs per group are given as percentage (% of mean±SD). (a) Top 30 of
most abundantly expressed miRs in CD4þ T cells of Sz syndrome, EAD, and healthy donors. (b) MiRs statistically significantly differentially expressed
in Sz syndrome versus EAD at an adjusted Po0.05. Individual adjusted P-values are listed in Supplementary Table S1 online. (c) MiRs statistically significantly
differentially expressed in Se´zary syndrome versus healthy controls at an adjusted Po0.05. Individual adjusted P-values are listed in Supplementary
Table S2 online.
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Figure 2. MicroRNA (miR) precursor analysis. Result of SYBR Green-based precursor quantitative PCR
(Q-PCR). Expression levels are relative to reference genes. Each bar represents one sample (duplicate
determination). Black bars: Se´zary, grey bars: atopic dermatitis, open bars: healthy donors.
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of the most differentially expressed
miRs when comparing Sz with controls,
contributing to 45% of all miRs in the
Sz miRNome. The clinical use of these
miRs and others identified in this study
as diagnostic/prognostic classifiers or
therapeutic targets warrants additional
validation in a larger patient cohort and
relevant control samples.
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